Clinical trials: Hypoglycemia
Type 1 Diabetes Mellitus
Study Assessing an Insulin Pump-controlling Algorithm to Minimize Hypo and Hyper in Type 1 During CRC Setting
Feasibility study assessing the ability of an insulin pump-controlling algorithm to minimize hypoglycemia and hyperglycemia in patients with type 1 diabetes in a clinical research setting.
- Trial name
- NCT01638299
- Testing
- Hypo-Hyper Minimizer (HHM) System
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Animas Corporation
Type 1 Diabetes
Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration
The purpose of this study is to evaluate the effectiveness of insulin delivered in the peritoneum (abdomen)by an implantable pump in Type 1 diabetics.
- Trial name
- MIP310 (NCT00211536)
- Testing
- Medtronic MiniMed Implantable Pump Human Recombinant Insulin, Medtronic MiniMed Implantable Pump System, Aventis HOE21PH U400
- Where
- 5 sites in United States
- Volunteers
- 107 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 1, Hypoglycemia
T1 Diabetes Hypoglycemia Prevention Pilot
A single center pilot study assessing the Vigilant Diabetes Management System for the prevention of recurrent mild to moderate hypoglycemia in type I diabetes patients.
- Trial name
- NCT02682940
- Testing
- Vigilant Diabetes Management Application
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- InSpark Technologies, Inc.
Healthy Volunteers and Diabetes Participants
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 Diabetes
This is a Phase 1/2 randomized study of oral doses of PAL-119 in healthy volunteers and participants with diabetes.
- Trial name
- NCT07901595
- Testing
- PAL-119
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Paulex Bio Inc.
Type 1 Diabetes Mellitus
A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SAR438544 in Comparison to Glucagon in Type 1 Diabetes Mellitus Patients Under Induced Hypoglycemia
Primary Objective: To assess the pharmacodynamic response (PD) of a single subcutaneous (SC) dose of SAR438544 versus recombinant glucagon in type 1 diabetes mellitus (T1DM) patients under induced hypoglycemia.
- Trial name
- NCT02635243
- Testing
- SAR438544, r-glucagon, insulin
- Sponsor
- Sanofi
Congenital Hyperinsulinism
A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
The objective of the trial is to evaluate the efficacy and safety of dasiglucagon administered as a subcutaneous (SC) infusion in reducing hypoglycemia in children with CHI.
- Trial name
- NCT03777176
- Testing
- Dasiglucagon, Standard of Care
- Where
- 10 sites in United States, Germany and 2 more
- Volunteers
- 32 people
- Sponsor
- Zealand Pharma
Hypoglycemia, Type 1 Diabetes
A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D
This research study will investigate whether dasiglucagon as a rescue therapy for participants under 6 years of age works and is safe to use.
- Trial name
- NCT05378672
- Testing
- Dasiglucagon
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Zealand Pharma
Hypoglycemia, Diabetes Mellitus
Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia
Up to two hundred (200) adult participants with type 1 diabetes (T1D) aged 18 to 75 years will be selected for inclusion in the study.
- Conditions
- Hypoglycemia, Diabetes Mellitus, Drug-Specific Antibodies
- Trial name
- NCT02171130
- Testing
- Nasal Glucagon
- Where
- 9 sites in United States, Canada
- Volunteers
- 129 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
Feasibility Study Assessing The Ability Of An Insulin Pump-Controlling Algorithm To Minimize Hypoglycemia And Hyperglycemia In Patients With Type 1 Diabetes In A Clinical Research Setting
The purpose of this study is to evaluate the performance of an insulin pump controlling algorithm while the subject is under close medical supervision in the Clinical Research Center (CRC) setting.
- Trial name
- NCT01401751
- Testing
- Hypoglycemia-Hyperglycemia Minimizer System
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Animas Corporation
Postbariatric Hypoglycemia
Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects
This clinical study will examine the safety and tolerability, as well as the effects of orally administered mizagliflozin on post prandial glucose and insulin levels in subjects diagnosed with post-bariatric hypoglycemia (PBH).
- Trial name
- NCT05541939
- Testing
- Mizagliflozin
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Vogenx, Inc.
Type 1 Diabetes Mellitus With Hypoglycemia
A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness
VC02-101 will evaluate an experimental cell replacement therapy intended to provide a functional cure to subjects with Type 1 Diabetes and Hypoglycemia Unawareness.
- Trial name
- NCT03163511
- Testing
- VC-02 Combination Product
- Where
- 10 sites in United States, Belgium and 1 more
- Volunteers
- 49 people
- Sponsor
- ViaCyte
Hypoglycemia
Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Marketed Glucagon
The trial is a single-centre, randomized, double-blind, parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of ZP4207 administered s.c.
- Trial name
- NCT02660008
- Testing
- ZP4207, GlucaGen
- Where
- Germany
- Volunteers
- 81 people
- Sponsor
- Zealand Pharma
Hypoglycemia
Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children
A phase 3, randomized, double-blind, placebo- and active-controlled, parallel-arm trial to assess the efficacy, safety, and pharmacokinetics of dasiglucagon relative to placebo and GlucaGen® when administered as a rescue therapy…
- Trial name
- NCT03667053
- Testing
- dasiglucagon, GlucaGen HypoKit
- Where
- 5 sites in United States, Germany and 1 more
- Volunteers
- 42 people
- Sponsor
- Zealand Pharma
Type 1 Diabetes Mellitus
Glucagon Rescue of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes Treated With Volagidemab
This trial is designed to evaluate the effect of glucagon receptor antagonism by volagidemab (once weekly) on glucose recovery from hypoglycemia after treatment with glucagon in adults with type 1 diabetes.
- Trial name
- NCT06272695
- Testing
- Volagidemab
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- REMD Biotherapeutics, Inc.
Hypoglycemia
Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV Administration
The purpose of the trial is to characterize the safety and tolerability of dasiglucagon 4 mg/mL following IV administration at increasing doses in healthy volunteers.
- Trial name
- NCT03735225
- Testing
- Dasiglucagon
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Zealand Pharma
Post-Bariatric Hypoglycemia
Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
The Total duration of trial participation for each participant with post-bariatric hypoglycemia will be a maximum of 59 weeks, with the following duration of trial periods 19 weeks for the Core Phase.
- Trial name
- PASIPHY (NCT05928390)
- Testing
- Pasireotide Diaspartate
- Where
- 29 sites in United States, Belgium and 4 more
- Volunteers
- 93 people
- Sponsor
- RECORDATI GROUP
Type 1 Diabetes, Type 1 Diabetes Mellitus With Hypoglycemia
Pilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes
First in Human, pilot investigation An Open Label, Monocentric, Pilot Study Evaluating Safety of ExOlin® in Patients with Poorly Controlled Type 1 Diabetes with High Glucose Fluctuations, Prone to Severe Hypoglycemia
- Trial name
- Pilot'Ex (NCT05221359)
- Testing
- ExOlin®, Insulin aspart
- Where
- France
- Volunteers
- 8 people
- Sponsor
- Defymed
Type II Diabetes Mellitus
A Non-Interventional Study To Evaluate Diabetes Related Quality Of Life, Frequency And Impact Of Hypoglycemia In T2DM
This is a non-interventional, cross sectional, multicentric study in T2DM patients which will involve a single visit for study related procedures.
- Trial name
- INSIGHT (NCT01523405)
- Where
- 70 sites in India
- Volunteers
- 4,911 people
- Sponsor
- AstraZeneca
Type 1 Diabetes
A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes
The main purpose of this study is to evaluate the safety and tolerability of a study drug called nasal glucagon (Baqsimi) in pediatric participants with type 1 diabetes (T1D) aged 1 to less than 4 years.
- Trial name
- RescuiNGkids (NCT04992312)
- Testing
- Glucagon Nasal Powder [Baqsimi]
- Where
- 8 sites in United States
- Volunteers
- 7 people
- Sponsor
- Eli Lilly and Company
Hypoglycemia, Diabetes Mellitus, Type 1
A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus
The purpose of this study is to compare a needle-free treatment of hypoglycemia with nasal glucagon (study drug) to a marketed glucagon administered by the intramuscular (IM) route, in participants with type 1 diabetes mellitus…
- Trial name
- NCT03339453
- Testing
- Nasal Glucagon, Intramuscular Glucagon
- Where
- 2 sites in Germany
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company